Stockscreener 앱 받기
8.34
0.72%
0.06
시간 외 거래:
8.43
0.09
+1.08%
전일 마감가:
$8.28
열려 있는:
$8.29
하루 거래량:
1.13M
Relative Volume:
0.81
시가총액:
$743.44M
수익:
$380.79M
순이익/손실:
$49.27M
주가수익비율:
11.91
EPS:
0.7
순현금흐름:
$10.68M
1주 성능:
+8.59%
1개월 성능:
+63.53%
6개월 성능:
+131.67%
1년 성능:
+317.00%
1일 변동 폭
$8.21
$8.59
1주일 범위
$7.76
$8.59
52주 변동 폭
$1.76
$8.59
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
명칭
Amylyx Pharmaceuticals Inc
전화
617-683-0917
주소
43 THORNDIKE STREET, CAMBRIDGE
AMLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
8.34 | 684.60M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Guggenheim | Buy |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-05-30 | 개시 | TD Cowen | Buy |
| 2025-04-07 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-11-18 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-03-18 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-11 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-07-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-01-05 | 개시 | BofA Securities | Buy |
| 2022-05-25 | 개시 | Citigroup | Buy |
| 2022-04-01 | 다운그레이드 | Goldman | Buy → Neutral |
모두보기
Amylyx Pharmaceuticals Inc 주식(AMLX)의 최신 뉴스
Promising Potential of Amylyx Pharmaceuticals’ Avexitide Program Drives Buy Rating - TipRanks
How Amylyx Pharmaceuticals Inc. stock performs during market volatilityFree Exclusive Group - Newser
What makes Amylyx Pharmaceuticals Inc. stock price move sharplyVolume Spike Monitors - Newser
Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion - Insider Monkey
Why Amylyx Pharmaceuticals Inc. stock attracts strong analyst attentionFree Capital Growth Strategies - Newser
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
TD Cowen reiterates Buy rating on Amylyx stock, cites avexitide potential - Investing.com
Amylyx Drug Slashes Sugar Spikes Post-Weight Loss SurgeryAmylyx Pharmaceuticals (NASDAQ:AMLX) - Benzinga
Citi maintains Buy rating on Amylyx Pharmaceuticals stock after KOL event By Investing.com - Investing.com South Africa
Amylyx presents new exploratory analyses from avexitide trials for PBH - Yahoo Finance
Citi maintains Buy rating on Amylyx Pharmaceuticals stock after KOL event - Investing.com
Amylyx Pharmaceuticals Reports Results of Phase 2b Post-Bariatric Hypoglycemia Clinical Trial - MarketScreener
Transcript : Amylyx Pharmaceuticals, Inc.Special Call - MarketScreener
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 - BioSpace
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded at The Goldman Sachs Group - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) Raised to “Buy” at The Goldman Sachs Group - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - ACCESS Newswire
Promising Potential of Avexitide Drives Amylyx Pharmaceuticals’ Growth Prospects - TipRanks
Goldman Sachs resumes Amylyx stock coverage with Buy rating on avexitide potential - Investing.com Nigeria
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out - ACCESS Newswire
Amylyx Pharmaceuticals Insiders Sell US$678k Of Stock, Possibly Signalling Caution - simplywall.st
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Amylyx (AMLX) Soars 3.25% on FDA Fast Track Designation - AInvest
Mitsubishi UFJ Financial Group, Inc. Announces Filing of Annual Report on Form 20-F for the Year Ended March 31, 2025 - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Amylyx Pharmaceuticals’ Phase 3 Study on Avexitide: A Potential Breakthrough for Post-Bariatric Hypoglycemia - TipRanks
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Amylyx Pharmaceuticals Advances Phase 3 Study on Avexitide for Post-Bariatric Hypoglycemia - TipRanks
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) added to Russell Small Cap Comp Growth Index - MarketScreener
Why Shares In Amylyx Pharmaceuticals Soared This Week - Barchart.com
After myriad failures, a new wave of ALS drugs approaches - Pharma Voice
Amylyx initiated with a Buy at Guggenheim on ‘blockbuster potential’ - TipRanks
Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash MarketAmylyx Pharmaceuticals (NASDAQ:AMLX) - Benzinga
Amylyx Pharmaceuticals (NASDAQ:AMLX) Coverage Initiated by Analysts at Citigroup - Defense World
Citi initiates Amylyx stock with buy rating on promising pipeline By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Citi initiates Amylyx stock with buy rating on promising pipeline - Investing.com
Amylyx Pharmaceuticals (AMLX): Citigroup Initiates Coverage with 'Buy' Rating | AMLX Stock News - GuruFocus
Amylyx initiated with a Buy at Citi - TipRanks
Amylyx (AMLX) Gains Positive Outlook with New Analyst Coverage | AMLX Stock News - GuruFocus
Diabetes Insipidus Market Statistics Expected to Experience - openPR.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Amylyx gets FDA fast track status for ALS treatment - MSN
Amylyx Pharmaceuticals (NASDAQ:AMLX) Lowered to Sell Rating by Wall Street Zen - Defense World
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of “Buy” by Brokerages - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation - ACCESS Newswire
# H.C. Wainwright reiterates Buy rating on AMYLYX stock ahead of trial - Investing.com India
Optimistic Buy Rating for Amylyx Pharmaceuticals’ AMX0114 Based on Promising ALS Treatment Mechanism and Trial Insights - TipRanks
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - ACCESS Newswire
Amylyx Pharmaceuticals Inc (AMLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.59%
0.34%
자본화:
|
볼륨(24시간):